Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

The Greens have come up with another justification for legalising cannabis, arguing it will help to solve Australia's cost of ...

Across healthcare system, stakeholders share blame for high costs. This includes hospitals, drugmakers, insurers and others ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

India’s CDMO market has seen a record growth trajectory due to cost advantages, technological advancements, and strong ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Explore how Medicare drug price negotiations under the Inflation Reduction Act could evolve with the Trump administration. Read more here.

Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

Public anger in China over concerns raised by doctors that generic drugs used in public hospitals are increasingly ...